Item 8.01 Other Events.
On September 22, 2020, Vaccinex, Inc. (the "Company") issued a press release
announcing data from the Company's Phase 2 SIGNAL trial evaluating pepinemab for
the treatment of Huntington's disease ("HD") in early manifest and late
prodromal (pre-manifest) HD patients. A copy of the press release is filed
herewith as Exhibit 99.1 and is incorporated by reference herein.
Previously, on September 17, 2020, the Company announced that it had entered
into a clinical collaboration agreement with a subsidiary of Merck & Co., Inc.
to evaluate pepinemab in combination with anti-PD-1checkpoint inhibitor
Keytruda® (pembrolizumab) in a Phase 1/2 clinical trial to treat advanced,
recurrent or metastatic head and neck squamous cell carcinoma.
Item 9.01 Financial Statements and Exhibits.
The following exhibits are filed herewith:
Exhibit Number Exhibit Description
99.1 Press Release, dated September 22, 2020
1
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses